Skip to main content
PLOS Genetics logoLink to PLOS Genetics
. 2009 Mar 24;5(3):10.1371/annotation/e0196ebb-de40-453f-8f8c-791b126618da. doi: 10.1371/annotation/e0196ebb-de40-453f-8f8c-791b126618da

Correction: A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia

Anna C Need, Dongliang Ge, Michael E Weale, Jessica Maia, Sheng Feng, Erin L Heinzen, Kevin V Shianna, Woohyun Yoon, Dalia Kasperavičiūtė, Massimo Gennarelli, Warren J Strittmatter, Cristian Bonvicini, Giuseppe Rossi, Karu Jayathilake, Philip A Cola, Joseph P McEvoy, Richard S E Keefe, Elizabeth M C Fisher, Pamela L St Jean, Ina Giegling, Annette M Hartmann, Hans-Jürgen Möller, Andreas Ruppert, Gillian Fraser, Caroline Crombie, Lefkos T Middleton, David St Clair, Allen D Roses, Pierandrea Muglia, Clyde Francks, Dan Rujescu, Herbert Y Meltzer, David B Goldstein
PMCID: PMC2706743

The authors declare the following competing interest, which should have been declared at the time of publication. Pamela L. St. Jean, Pierandrea Muglia, and Clyde Francks are full-time employees of GlaxoSmithKline, a pharmaceutical company that is developing treatments for schizophrenia and that has filed patent applications for SNPs related to schizophrenia (United States Patent Applications 20080176239 and 20080176240, and International Application No.: PCT/EP2008/050477).


Articles from PLoS Genetics are provided here courtesy of PLOS

RESOURCES